Aviado · Research
Longevity Daily
Monday, November 16, 2026
Listen
Today's Brief
Today's lead is a brain-aging intervention hiding in plain sight: a high-dose flu vaccine is linked to up to 22% lower Alzheimer's risk — making your annual shot choice genuinely consequential. A Yale meta-analysis of 51 trials confirms metformin and semaglutide slow epigenetic aging while most OTC supplements don't; Aviado Research's EPA piece shows what good mechanistic evidence looks like. Peter Attia's new mitochondria deep-dive with Nav Chandel is essential listening, and fresh Nature Aging findings on social isolation remind us that some longevity inputs don't fit in a pill organizer.
10 stories3 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
High-Dose Flu Vaccine Linked to Up to 22% Lower Alzheimer's Risk
Researchers found that people who received a high-dose influenza vaccine had up to 22% lower risk of developing Alzheimer's disease over the following two years compared to those given a standard-dose shot, with some analyses suggesting the benefit could approach 55% over longer time horizons. The finding adds to a growing body of evidence that immune activation and neuroinflammation are central to Alzheimer's pathology, and that vaccines may confer neuroprotective benefits well beyond their intended purpose. For adults 65 and older, who are already recommended the high-dose formulation, this research adds meaningful brain-health weight to that conversation with your doctor. This is observational data rather than a randomized trial, so causation is not proven, but the effect size and biological plausibility make it one of the most actionable preventive signals in brain aging this year.
Read more →Hormone Therapy Tied to Better Memory and Larger Brain Volumes in APOE4-Positive Women
A European cohort study of 1,178 women, highlighted at Neuroscience 2026, found that hormone therapy was linked to better memory performance and larger brain volumes in women carrying the APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer's disease. The benefit was most pronounced when therapy began around the time of menopause, suggesting a timing-dependent neuroprotective window that closes if treatment is delayed. For women who know their APOE4 status, this adds real weight to the conversation about when, not just whether, to consider menopausal hormone therapy.
Read more →GLP-1 Weight-Loss Drugs Are Reshaping Brain Function in Ways Science Is Only Beginning to Map
A new review from the University of Copenhagen finds that GLP-1 receptor agonists, the drug class behind Ozempic and Wegovy, appear to influence brain metabolism, appetite regulation, and potentially cognition through mechanisms that extend well beyond weight loss. Senior author Christoffer Clemmensen describes these drugs as opening new opportunities to understand how metabolic regulation influences brain function. The implications for cognitive aging and Alzheimer's risk are still speculative, but the brain connection is gaining scientific momentum fast.
Read more →Supplements & Compounds
EPA Cuts Triglycerides 15-30% by Blocking VLDL Assembly: Why It Outperforms Generic Fish Oil
Most people assume all omega-3s work the same way, but Aviado Research's latest analysis shows EPA and DHA are functionally distinct. EPA specifically blocks VLDL particle assembly in the liver, the step that releases triglycerides into circulation, producing a reliable 15-30% reduction across studies tracking over 160,000 people. If you're taking omega-3s for triglyceride management, the evidence points clearly to EPA-dominant formulations at 2-4 grams daily, not generic mixed fish oil.
Read the full Aviado analysis →Yale's 51-Trial Meta-Analysis: Metformin and Semaglutide Slow Biological Aging, Most Supplements Don't
A Yale School of Medicine analysis of 51 clinical trials published in Nature Medicine finds that prescription drugs, metformin, semaglutide, and anti-TNF agents, measurably lower epigenetic age markers, while popular over-the-counter supplements showed little to no effect in the same analysis. This is a significant reality check for the longevity supplement market: every intervention with a meaningful biological aging signal in this dataset is prescription-only. If you're stacking NMN, resveratrol, or similar compounds specifically for epigenetic age reduction, this study is worth reading before your next order.
Read more →Research & Papers
The Fasting-Mimicking Diet Is Having Its Moment, and Stanford's Data Explains Why
The fasting-mimicking diet, which allows food intake while triggering cellular responses similar to water fasting, is gaining serious clinical traction after a landmark Stanford trial found nearly 70% of participants showed significant improvements after three FMD cycles compared to controls. Unlike prolonged fasting, FMD involves just five days per month of reduced, specifically structured calorie intake, making adherence far more realistic for most people. The Stanford results have moved FMD from niche biohacker territory into mainstream clinical research, and the momentum appears to be accelerating.
Read more →Peter Attia and Nav Chandel Break Down What We Actually Know About Mitochondria, Aging, and Supplements
In episode 416 of The Drive, Peter Attia sits down with mitochondrial researcher Navdeep Chandel, Ph.D., to unpack how mitochondrial dysfunction contributes to aging and what the evidence actually says about drugs and supplements marketed to improve mitochondrial function. Chandel's framing is clarifying: the problem in aging may be mitochondrial miscommunication rather than simple energy depletion, which reshapes how we should evaluate interventions from NAD+ precursors to metformin. For anyone taking mitochondria-targeted supplements, this episode is essential listening before your next reorder.
Read more →Lifestyle & Nutrition
Elite VO2 Max Cuts Mortality Risk by 80%: Two Weekly Strength Sessions Make It Even Better
New analysis reinforces what exercise researchers have long argued: cardiovascular fitness and muscular strength are complementary longevity levers, not competing priorities. An elite VO2 max is associated with up to 80% lower mortality risk, but adding just two short resistance training sessions per week delivers an additional longevity dividend on top of that. For cardio-only exercisers, this is a strong signal that two weekly strength sessions may be one of the highest-return adjustments available.
Read more →Social Isolation Is One of the Biggest Modifiable Longevity Risks, and It Won't Fit in Your Pill Organizer
A new review in Nature Aging argues that social isolation and loneliness rank among the most powerful modifiable risk factors for early death, with a mortality impact comparable to smoking and physical inactivity. The piece is a pointed reminder for the longevity optimization community, which tends to focus on biomarkers, protocols, and supplement stacks: community and connection may outperform your entire supplement regimen on the mortality chart. Joining a club, maintaining close friendships, and actively reducing chronic isolation appear to be severely underrated longevity interventions.
Read more →Industry & Policy
The Longevity Supplement Boom Has a Regulatory Problem, and Industry Insiders Are Flagging It
At last week's Nutra Healthspan Summit in London, an expert panel highlighted a widening gap: the healthy longevity supplement category is booming commercially, but regulatory frameworks have not kept pace with the science or the market, leaving companies constrained to vague health claims on products with real mechanistic evidence. The mismatch creates real consumer confusion: when everything says supports healthy aging, nothing means anything. The debate has practical implications for anyone trying to evaluate longevity supplement labels.
Read more →